TEE
SBBP

Tibra Equities Europe’s Strongbridge Biopharma plc. SBBP Stock Holding History

Tibra Equities Europe’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-64,985
Closed -$324K – 498
2019
Q1 		$324K Buy
+64,985
New +$320K 0.03% 323

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Tibra Equities Europe's SBBP Position: Q2 2019 in Review

Tibra Equities Europe sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2019, closing a stake of 64,985 shares — an estimated $324K sold.

Tibra Equities Europe first reported a position in SBBP in Q1 2019 and held it in 1 quarter. The position peaked at $324K in Q1 2019. 58 funds tracked by Wall St. Rank hold SBBP as of Q2 2019.

  • Tibra Equities Europe reported no remaining Strongbridge Biopharma plc. position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 64,985 Strongbridge Biopharma plc. shares in Q2 2019, an estimated $324K.
  • Tibra Equities Europe first reported a position in Strongbridge Biopharma plc. in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Strongbridge Biopharma plc. position peaked at $324K in Q1 2019.
  • 58 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.